<DOC>
	<DOC>NCT00958438</DOC>
	<brief_summary>The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout. Subjects will participate in this study for approximately 22 weeks. Rilonacept is being studied for use in preventing allopurinol-induced gout flares.</brief_summary>
	<brief_title>PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Male or female 18 to 80 years of age Previously met the preliminary criteria of the ARA for the classification of the acute arthritis of primary gout At least 2 gout flares in the year prior to the Screening Visit Serum uric acid greater than or equal to 7.5 mg/dL at the Screening Visit Acute gout flare within 2 weeks of the Screening Visit or during Screening Persistent chronic or active infections History of an allergic reaction to allopurinol History or presence of cancer within 5 years of the Screening Visit Previous exposure to rilonacept Use of allopurinol, benzbromarone, febuxostat, probenecid or sulfinpyrazone within 3 months prior to the Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Intercritical Gout</keyword>
	<keyword>Metabolism, Inborn Errors</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Genetic Diseases, Inborn</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Metabolic disorder</keyword>
	<keyword>Purine-Pyrimidine Metabolism, Inborn Errors</keyword>
	<keyword>Gout</keyword>
</DOC>